ARBUTUS BIOPHARMA CORP.
Updated: Jun 1
Arbutus Biopharma Corp. is a biopharmaceutical company that specializes in the discovery, development, and commercialization of therapies for the treatment of chronic hepatitis B virus (HBV) infection. The company was founded in 2008 and is headquartered in Warminster, Pennsylvania.
One of the key strengths of Arbutus Biopharma is its focus on HBV, a global health challenge that affects an estimated 250 million people worldwide. The company is committed to developing innovative therapies that can address the underlying cause of HBV infection and provide patients with a cure for the disease. Arbutus Biopharma's HBV program is based on a deep understanding of the biology of the virus and its interaction with the human immune system, and the company is a recognized leader in the field of HBV research and development.
Another area where Arbutus Biopharma excels is in its expertise in RNA interference (RNAi) technology, a powerful tool for the selective silencing of disease-causing genes. The company has a proprietary RNAi platform that allows for the development of highly specific and effective therapies for a range of diseases, including HBV. Arbutus Biopharma's RNAi technology has been validated in preclinical and clinical studies, and the company has several potential RNAi-based therapies in development for the treatment of HBV and other diseases.
Arbutus Biopharma has a global presence, with operations and partnerships in several countries around the world. The company's global reach allows it to efficiently and effectively deliver its therapies and solutions to patients and healthcare providers, regardless of their location.
In addition to its HBV program, Arbutus Biopharma also has a pipeline of therapies in development for the treatment of other viral diseases, including respiratory syncytial virus (RSV) and human papillomavirus (HPV). The company's expertise in RNAi technology has the potential to enable the development of highly specific and effective therapies for a range of viral diseases, further expanding its opportunities for growth and success.
In recent years, Arbutus Biopharma has continued to advance its pipeline of therapies through partnerships and collaborations. The company has established partnerships with several leading pharmaceutical companies, including Roivant Sciences and Alexion Pharmaceuticals, to accelerate the development of its RNAi-based therapies and to expand its commercial opportunities.
Arbutus Biopharma Corp. is a biopharmaceutical company that has built a reputation for its focus on HBV, expertise in RNAi technology, commitment to innovation, and strong partnerships. With a range of potential therapies in development, a focus on research and development, and a commitment to meeting the evolving needs of patients and healthcare providers, the company is well-positioned to continue its success in the years to come.